NFE2L2 and liver cancer: By interfering with the Nrf2 binding site and preventing it from binding to Keap1, it can alter the expression of kelch-like ECH-associated protein-1 (Keap1), a liver cancer factor, and increase the expression of essential antioxidative signals like HO-1 [88].